Comparison of anti SARS CoV 2 activity and intracellular metabolism of remdesivir and its parent nucleoside
Remdesivir, a monophosphate prodrug of nucleoside analog GS 441524, is widely used for the treatment of moderate to severe COVID 19. It has been suggested to use GS 441524 instead of remdesivir in the clinic and in new inhalation formulations. Thus, we compared the anti SARS CoV 2 activity of remdesivir and GS 441524 in Vero E6, Vero CCL 81, Calu 3, Caco 2 cells, and anti HCoV OC43 activity in Huh 7 cells. We also compared the cellular pharmacology of these two compounds in Vero E6, Vero CCL 81, Calu 3, Caco 2, Huh 7, 293T, BHK 21, 3T3 and human airway epithelial (HAE) cells. Overall, remdesivir exhibited greater potency and superior intracellular metabolism than GS 441524 except in Vero E6 and Vero CCL 81 cells.
Current Research in Pharmacology and Drug Discovery